全文获取类型
收费全文 | 38845篇 |
免费 | 3535篇 |
国内免费 | 1877篇 |
专业分类
耳鼻咽喉 | 319篇 |
儿科学 | 424篇 |
妇产科学 | 680篇 |
基础医学 | 7989篇 |
口腔科学 | 814篇 |
临床医学 | 2253篇 |
内科学 | 4724篇 |
皮肤病学 | 825篇 |
神经病学 | 2265篇 |
特种医学 | 638篇 |
外国民族医学 | 13篇 |
外科学 | 2484篇 |
综合类 | 5956篇 |
现状与发展 | 7篇 |
预防医学 | 1592篇 |
眼科学 | 318篇 |
药学 | 3765篇 |
6篇 | |
中国医学 | 1227篇 |
肿瘤学 | 7958篇 |
出版年
2024年 | 69篇 |
2023年 | 566篇 |
2022年 | 846篇 |
2021年 | 1421篇 |
2020年 | 1132篇 |
2019年 | 989篇 |
2018年 | 886篇 |
2017年 | 993篇 |
2016年 | 1016篇 |
2015年 | 1324篇 |
2014年 | 1894篇 |
2013年 | 1990篇 |
2012年 | 1870篇 |
2011年 | 2395篇 |
2010年 | 2074篇 |
2009年 | 2164篇 |
2008年 | 2234篇 |
2007年 | 2292篇 |
2006年 | 2097篇 |
2005年 | 1907篇 |
2004年 | 1840篇 |
2003年 | 1757篇 |
2002年 | 1521篇 |
2001年 | 1410篇 |
2000年 | 1288篇 |
1999年 | 1061篇 |
1998年 | 894篇 |
1997年 | 774篇 |
1996年 | 660篇 |
1995年 | 553篇 |
1994年 | 395篇 |
1993年 | 286篇 |
1992年 | 223篇 |
1991年 | 161篇 |
1990年 | 118篇 |
1989年 | 113篇 |
1988年 | 102篇 |
1987年 | 74篇 |
1986年 | 73篇 |
1985年 | 112篇 |
1984年 | 113篇 |
1983年 | 47篇 |
1982年 | 88篇 |
1981年 | 77篇 |
1980年 | 69篇 |
1979年 | 49篇 |
1978年 | 52篇 |
1977年 | 39篇 |
1976年 | 33篇 |
1975年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 328 毫秒
1.
2.
《Vaccine》2022,40(32):4296-4300
Advanced computational methodologies suggested SARS-CoV-2, nonstructural proteins ORF1AB, ORF3a, as the source of immunodominant peptides for T cell presentation. T cell immunity is long-lasting and compatible with COVID-19 pathology. Based on the supporting clinical data, nonstructural SARS-CoV-2 protein vaccines could provide global immunity against COVID-19. 相似文献
3.
Lei Yang You-Ling Shi Yan Ma Wei-Wei Ren Guang-Ming Pang Jiao Liu 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2022,130(1):43-52
Krüppel-like factor 16 (KLF16), a member of the Krüppel-like factor (KLF) family, has been extensively investigated in multiple cancer types. However, the role of KLF16 in oral squamous cell carcinoma (OSCC) remains unknown. Thus, we conducted this study to investigate its related mechanism. KLF16 expression in OSCC cell lines was quantified by western blotting. Then, OECM1 and OC3 cells were divided into Blank, siCtrl, siKLF16#1 and siKLF16#2 groups. Subsequently, cell proliferation was detected using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assays, cell migration and invasion were detected with wound healing and Transwell assays, and cell cycle distribution and cell apoptosis were detected via flow cytometry. KLF16, p21, CDK4, Cyclin D1 and p-Rb expression was detected by western blotting. Finally, xenograft models were established in nude mice to observe the in vivo effects of KLF16 on OSCC. KLF16 protein expression was upregulated in OSCC cells. Compared to the cells in the Blank group, the OECM1 and OC3 cells in the siKLF16#1 group and siKLF16#2 group exhibited a sharp decrease in proliferation but a remarkable increase in apoptosis. Moreover, the proportion of cells in the G0/G1 phase notably increased and that in the S phase decreased, with evident decreases in cell invasion and migration. Moreover, KLF16, cyclin-dependent kinase 4 (CDK4), Cyclin D1 and p-Rb protein expression was upregulated, but p21 expression was downregulated. The mice in the siKLF16#1 and siKLF16#2 xenograft model groups exhibited slower tumour growth and smaller tumours with evident downregulation of Ki67 expression compared to the mice in the Blank group. KLF16 expression was upregulated in OSCC cells, and interfering with KLF16 led to cell cycle arrest, inhibited OSCC cell growth and promoted cell apoptosis. 相似文献
4.
Lipid nanoparticles (LNPs) are becoming popular as a means of delivering therapeutics, including those based on nucleic acids and mRNA. The mRNA-based coronavirus disease 2019 vaccines are perfect examples to highlight the role played by drug delivery systems in advancing human health. The fundamentals of LNPs for the delivery of nucleic acid- and mRNA-based therapeutics, are well established. Thus, future research on LNPs will focus on addressing the following: expanding the scope of drug delivery to different constituents of the human body, expanding the number of diseases that can be targeted, and studying the change in the pharmacokinetics of LNPs under physiological and pathological conditions. This review article provides an overview of recent advances aimed at expanding the application of LNPs, focusing on the pharmacokinetics and advantages of LNPs. In addition, analytical techniques, library construction and screening, rational design, active targeting, and applicability to gene editing therapy have also been discussed. 相似文献
5.
目的:探讨胃癌患者根治术后腹腔冲洗液中CEA mRNA表达情况及其临床意义。方法: 回顾性分析了2013 年1 月至2017 年12 月在南京大学医学院附属鼓楼医院接受胃癌根治切除术后进行腹腔灌洗液CEA mRNA检测的139 名患者的病历资料,并进行术后常规随访。用RT-PCR检测139 胃癌患者根治术后腹腔灌洗液中CEA mRNA表达情况。卡方检验分析腹腔灌洗液中CEA mRNA表达与临床基本特征、组织病理学资料、血液学指标及复发方式之间的关系。采用Logistic 单因素及多因素回归分析筛查影响CEA mRNA表达水平的因素。结果:139 名患者中44 名(31.7%)患者腹腔灌洗液CEA mRNA阳性。分析显示,胃癌患者腹腔灌洗液CEA mRNA阳性表达与性别、年龄、病理分级、Lauren 分型和HER2、EGFR、VEGFR等标记物间均没有明显的关联(均P>0.05),与病理类型、脉管是否侵犯、局部浸润深度、淋巴结转移程度和临床AJCC 分期有明显的关联(均P<0.05)。CEA mRNA阳性患者腹膜复发率明显高于阴性患者(P=0.012)。Logistic 单因素回归分析显示,印戒细胞癌(P=0.04,HR=2.810,95% CI: 1.050~7.520)、T 分期(P=0.016,HR=6.329,95% CI: 1.417~28.264)、N 分期(P=0.022,HR=3.068,95% CI: 1.172~8.027)、AJCC分期(P=0.016 ,HR=3.971 ,95% CI: 1.295~12.173 )、神经侵犯(P=0.002 ,HR=6.738,95% CI: 1.995~22.757)、脉管侵犯(P<0.001,HR=16.36,95% CI: 3.85~69.512)为胃癌患者腹腔灌洗液CEA mRNA阳性表达的危险因素。Logistic 多因素回归分析显示,经过对其他因素的校正,脉管侵犯(P<0.001,HR=21.314,95% CI: 4.21~107.907)为胃癌患者腹腔灌洗液CEA mRNA阳性表达的独立危险因素。结论:胃癌腹腔灌洗CEA mRNA阳性的患者腹膜复发转移风险高且预后不良,应考虑包括腹腔局部治疗在内的更加积极的抗肿瘤治疗。 相似文献
6.
《Vaccine》2016,34(39):4724-4731
Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. HPVs are oncogenic small double-stranded DNA viruses that are the primary causal agent of cervical cancer and other types of cancers, including in the anus, oropharynx, vagina, vulva, and penis. Prophylactic vaccination against HPV is an attractive strategy for preventing cervical cancer and some other types of cancers. However, there are few safe and effective vaccines against HPV infections. Current first-generation commercial HPV vaccines are expensive to produce and deliver.The goal of this study was to develop an alternate potent HPV recombinant L1-based vaccines by producing HPV virus-like particles into a vaccine that is currently used worldwide. Live attenuated measles virus (MV) vaccines have a well-established safety and efficacy record, and recombinant MV (rMV) produced by reverse genetics may be useful for generating candidate HPV vaccines to meet the needs of the developing world.We studied in non-human primate rMV-vectored HPV vaccine in parallel with a classical alum adjuvant recombinant HPV16L1 and 18L1 protein vaccine produced in Pichia pastoris. A combined prime-boost approach using both vaccines was evaluated, as well as immune interference due to pre-existing immunity against the MV.The humoral immune response induced by the MV, Pichia-expressed vaccine, and their combination as priming and boosting approaches was found to elicit HPV16L1 and 18L1 specific total IgG and neutralizing antibody titres. Pre-existing antibodies against measles did not prevent the immune response against HPV16L1 and 18L1. 相似文献
7.
Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features 下载免费PDF全文
8.
9.
Ignasi Esteban Carmen Pastor-Quiones Lorena Usero Montserrat Plana Felipe García Lorna Leal 《Viruses》2021,13(3)
Over 36 million people worldwide are infected with HIV. Antiretroviral therapy (ART) has proven to be highly effective to prevent HIV-1 transmission, clinical progression and death. Despite this success, the number of HIV-1 infected individuals continues increasing and ART should be taken for life. Therefore, there are two main priorities: the development of preventive vaccines to protect from HIV acquisition and achieve an efficient control of HIV infection in the absence of ART (functional cure). In this sense, in the last few years, there has been a broad interest in new and innovative approaches such as mRNA-based vaccines. RNA-based immunogens represent a promising alternative to conventional vaccines because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. Some mRNA-based vaccines platforms against infectious diseases have demonstrated encouraging results in animal models and humans. However, their application is still limited because the instability and inefficient in vivo delivery of mRNA. Immunogens, design, immunogenicity, chemical modifications on the molecule or the vaccine delivery methods are all crucial interventions for improvement. In this review we, will present the current knowledge and challenges in this research field. mRNA vaccines hold great promises as part of a combined strategy, for achieving HIV functional cure. 相似文献
10.